Korea South
PharmCADD, founded in 2019 and headquartered in Korea South, is leveraging state-of-the-art technologies to revolutionize drug discovery. The company combines Artificial Intelligence (AI), Molecular Dynamics (MD), Quantum Calculation (QC), and Network Theory to enhance both the speed and accuracy of discovering new drugs. Their approach significantly reduces the need for maintaining costly infrastructure associated with traditional high-performance computational resources.
The integration of data-derived AI with physics-based MD and QC technologies provides a competitive edge, allowing PharmCADD to precisely characterize drug candidates amidst a sprawling chemical landscape. This tech-driven approach aligns perfectly with current industry trends, positioning the company as a potentially transformative player in the AI, Biotechnology, and Pharmaceutical sectors.
With a recent $16.00M Series B investment on April 19, 2021, which included financiers like DSC Investment and KTB Network, PharmCADD is poised for further growth and innovation in its mission to streamline drug discovery.
